Impact of baseline thrombocytopenia on bleeding and mortality after Venous thromboembolism: from the COMMAND VTE Registry-2

Abstract

Abstract Background and Aims The impact of baseline thrombocytopenia on the long-term clinical outcomes has not been clarified in patients with venous thromboembolism (VTE) during the direct oral anti-coagulant (DOAC) era. Methods This study sought to evaluate an association of baseline thrombocytopenia with major bleeding, recurrent VTE, and mortality risk in patients with VTE. This study included 5173patients from the COntemporary ManageMent AND outcomes in patients with Venous ThromboEmbolism (COMMAND-VTE) Registry-2. Thrombocytopenia was defined as platelet count of <150×109/L and was classified into moderate/severe (<100×109/L) and mild (≧100-<150×109/L), based on the previous reports. Results At 5 years after index admission, the moderate/severe thrombocytopenia group had a significantly higher cumulative major bleeding than the no thrombocytopenia group (log-rank test, p<0.001). Moreover, the moderate/severe thrombocytopenia group had a significantly higher cumulative all-cause mortality rates than the no thrombocytopenia group (log-rank test, p < 0.001). Conclusions Baseline platelet level could be a prognostic marker for risk stratification.